Healthcare Stocks — Analysis & Key Financial Data
The healthcare sector includes pharmaceuticals, biotech, medical devices, and healthcare services. Demographic trends and innovation drive long-term demand, while regulation and pipeline risk affect individual names. Browse 460 healthcare stocks with proprietary Investment Scores, base valuations, and key financial data to make informed decisions.
Sector Investment Score
Highest Investment Scores in Healthcare
Top-rated stocks by Investment Score
- Price
- $170.89
- Fair Value
- $788.81
- Market Cap
- $991M
- Margin
- +361.6%
- Price
- $113.36
- Fair Value
- $75.59
- Market Cap
- $22.7B
- Margin
- -33.3%
- Price
- $36.41
- Fair Value
- $78.65
- Market Cap
- $2.1B
- Margin
- +116.0%
- Price
- $194.88
- Fair Value
- $192.11
- Market Cap
- $29.1B
- Margin
- -1.4%
Healthcare Stock List
| Company | Price | Fair Value | Score | Market Cap | P/E | EPS | Yield |
|---|---|---|---|---|---|---|---|
Eli Lilly and Company LLY | $1229.93 | $503.90 | 65 | $1.14T | 42.8 | $28.26 | 0.54% |
Johnson & Johnson JNJ | $258.51 | $140.16 | 65 | $613.0B | 29.4 | $8.60 | 2.06% |
AbbVie Inc. ABBV | $254.31 | $201.97 | 52 | $444.4B | 123.3 | $2.05 | 2.68% |
UnitedHealth Group Incorporated UNH | $419.82 | $803.62 | 58 | $388.6B | 32.3 | $13.24 | 2.09% |
Merck & Co., Inc. MRK | $129.38 | $173.65 | 65 | $317.1B | 36.1 | $3.61 | 2.62% |
Novartis AG NVS | $157.59 | $68.69 | 74 | $296.5B | 22.4 | $7.06 | 2.93% |
Amgen Inc. AMGN | $360.55 | $421.52 | 77 | $193.4B | 24.8 | $14.44 | 2.73% |
Thermo Fisher Scientific Inc. TMO | $506.42 | $426.61 | 55 | $190.7B | 28.2 | $18.44 | 0.35% |
Abbott Laboratories ABT | $92.71 | $72.26 | 61 | $163.4B | 26.1 | $3.59 | 2.60% |
Gilead Sciences, Inc. GILD | $126.33 | $85.15 | 77 | $158.8B | 17.2 | $7.42 | 2.52% |
Intuitive Surgical, Inc. ISRG | $405.97 | $164.34 | 71 | $143.3B | 48.4 | $8.39 | 0.00% |
Danaher Corporation DHR | $192.78 | $80.10 | 48 | $138.5B | 37.7 | $5.21 | 0.74% |
Pfizer Inc. PFE | $24.37 | $69.32 | 52 | $138.4B | 18.5 | $1.32 | 7.08% |
CVS Health Corp. CVS | $103.58 | $161.03 | 45 | $133.1B | 45.2 | $2.30 | 2.55% |
Stryker Corporation SYK | $330.52 | $301.10 | 65 | $127.4B | 38.1 | $8.72 | 1.04% |
Vertex Pharmaceuticals Incorporated VRTX | $499.65 | $375.04 | 74 | $124.7B | 28.9 | $17.07 | 0.00% |
Bristol-Myers Squibb Company BMY | $58.56 | $58.10 | 71 | $117.5B | 16.2 | $3.56 | 4.35% |
Medtronic plc MDT | $80.93 | $64.79 | 74 | $103.7B | 21.6 | $3.74 | 3.52% |
McKesson Corporation MCK | $747.53 | $792.08 | 74 | $89.4B | 19.8 | $39.00 | 0.43% |
HCA Healthcare, Inc. HCA | $392.33 | $992.05 | 68 | $86.9B | 13.4 | $29.98 | 0.77% |
Elevance Health Inc. ELV | $388.03 | $879.00 | 58 | $85.8B | 16.8 | $23.78 | 1.74% |
Cigna Corporation CI | $278.74 | $918.62 | 74 | $74.8B | 11.9 | $23.95 | 2.17% |
Boston Scientific Corporation BSX | $43.48 | $42.48 | 81 | $65.7B | 18.4 | $2.39 | 0.00% |
Regeneron Pharmaceuticals, Inc. REGN | $631.81 | $967.36 | 84 | $65.2B | 14.9 | $42.53 | 0.58% |
Becton, Dickinson and Company BDX | $155.19 | $176.70 | 52 | $56.5B | 39.5 | $4.06 | 2.40% |
Explore Healthcare Sub-Categories
About the healthcare sector
Healthcare spans a wider range of business models than almost any other sector. A large pharmaceutical company with marketed drugs, dependable cash flow, and a patent-cliff calendar is a fundamentally different investment than a clinical-stage biotech whose value hinges on a single Phase 3 readout. Both sit inside Healthcare, and both appear on this screener page run through the same valuation pipeline.
The screener treats every name mechanically. The Investment Score weighs profitability and balance-sheet quality regardless of where a company sits on the commercialisation curve, which means an established pharma with strong cash generation can score high while a pre-revenue biotech with a deep loss profile scores low — even if the biotech is the more interesting pipeline story. The score is one input. The page also shows base valuation, growth profile, and the underlying financials so the picture is visible.
Sub-industries inside Healthcare get their own screener pages. Pharma and biotech are the two largest groupings; the AI-in-healthcare and cannabis tags pick up names that span sectors and are shown wherever they fit in our taxonomy.
What this page is for
This page is a screener and reference surface, not editorial coverage. The list above refreshes with each data update; the methodology, FAQ, and related categories below stay in place so the page is useful both for somebody arriving from a specific search and for somebody scanning the sector for the first time.
If you want to value a single healthcare stock end-to-end rather than scan the sector, the Invest Viable Valuator walks through the same models we use to compute the base valuations on this page.
Sub-industries within Healthcare
Themes within this sector get their own screener pages. Each one applies the same Investment Score model and base valuation to a narrower group of companies.
- Pharma StocksLarge pharmaceutical companies with marketed drug portfolios, established cash flows, and patent-cliff risk that drives the next wave of acquisitions and pipeline activity.
- Biotech StocksClinical and pre-revenue biotechs through to commercial-stage names. Valuation depends on trial readouts and probability-weighted approval timelines as much as on current financials.
- AI in HealthcareCompanies applying machine learning to drug discovery, diagnostics, or clinical workflow — sits at the boundary between Healthcare and Technology and shows up on both screener pages.
- Cannabis StocksMedical and adult-use cannabis operators. Heavily regulated, capital-intensive, and traded on multiple exchanges including OTC venues — shown here when classified into Healthcare by our taxonomy.
How we screen healthcare stocks
Every stock listed on this page has been classified into the Healthcare sector by our taxonomy and run through the same Investment Score model and base-valuation pipeline used across the site. The list is mechanical — no editorial weighting.
- Listed on a US exchange (NYSE / Nasdaq) and classified as Healthcare in our sector taxonomy. ADRs of foreign-domiciled healthcare names appear when their primary US listing is active.
- Sufficient public financial history to compute the metrics shown — revenue, gross margin, R&D as % of sales, free cash flow, balance-sheet items.
- Ingested by our data pipeline within the last update window. Stocks awaiting refresh are not surfaced.
- Investment Score and base valuation computed by the same models used elsewhere on Invest Viable. The score evaluates profitability, balance-sheet quality, and growth — the formula itself is proprietary.
Frequently asked questions
How many stocks are in the Healthcare sector on Invest Viable?
The exact count is shown in the hero above and refreshes with each data update. The Healthcare sector covers pharmaceuticals, biotechnology, medical devices, healthcare equipment, healthcare services, and managed care. Cannabis names that our taxonomy classifies as healthcare also appear here.
How is Healthcare different from a Biotech-only screener?
Healthcare is the broader sector — it includes commercial-stage pharma, medical-device makers, hospitals, payors, and biotech. The dedicated Biotech Stocks page narrows the same data to biotech only, where most names are pre-revenue or single-product and valuation runs on probability-weighted pipeline outcomes rather than current cash flow.
How are healthcare stocks valued differently from other sectors?
Mature pharma and medical-device companies are valued similarly to other industrials — DCF on free cash flow, multiples on earnings. Biotech and clinical-stage names need a different lens — probability-of-success weighting on pipeline, royalty terms, and time-to-cash-flow. Our base valuations apply both methods on a per-stock basis where the data supports it, and the Investment Score reflects financial health regardless of where a company sits on the lifecycle curve.
Why do biotech stocks sometimes show very large negative margins of safety?
A negative margin of safety means market price is above the base valuation our default models compute. For early-stage biotech with little or no revenue, default DCF assumptions can produce conservative base values that markets routinely trade above when investors price in pipeline optionality. The number flags the gap rather than passing judgement on it.
Does Invest Viable recommend specific healthcare stocks?
No. This page is a screener and analysis surface, not a recommendation list. Each stock is shown with its underlying financial data, base valuation, and Investment Score so you can do your own research. Invest Viable does not publish buy or sell calls on individual securities.
Related screener pages
Related Themes
By Style
Find undervalued healthcare stocks with professional valuation tools
Set your own price targets using DCF, EBITDA multiples, and Graham Fair Value methods. Compare your valuations against our base estimates and make confident investment decisions.
Disclaimer: The information provided on this page is for informational and educational purposes only and does not constitute investment advice, financial advice, or any recommendation to buy, sell, or hold any security. Investment Scores, base valuations, and fair value estimates are generated using proprietary models and should not be the sole basis for any investment decision. All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Invest Viable AB is not a registered investment advisor.